Education
About Us
Working with TipRanks
Follow Us
Actinium Pharmaceuticals (ATNM)
:ATNM
ATNM Analyst Ratings
Strong Buy
3 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
ATNM Stock 12 Month Forecast
Average Price Target
$6.00
▲(270.37% Upside)
| Highest Price Target$9.00 | Average Price Target$6.00 | Lowest Price Target$4.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
H.C. Wainwright
$4
Buy
146.91%
Upside
Reiterated
07/31/25
Actinium Pharmaceuticals' ATNM-400 Shows Promise in Prostate Cancer Treatment, Earning Buy RatingValuation and risks to price target achievement. We reiterate our Buy rating and $4 price target. Our current valuation includes only Actimab-A for AML (82% contribution) and Iomab-ACT, which recently had its IND approved (18% contribution). Our valuation is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug's potential commercial profile.
JonesTrading
$9
Buy
455.56%
Upside
Reiterated
06/25/25
Maxim Group
$5
Buy
208.64%
Upside
Reiterated
05/13/25
Stephens
$5
Buy
208.64%
Upside
Reiterated
11/19/24
B.Riley Financial
$16→$2
Hold
23.46%
Upside
Downgraded
08/07/24
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
H.C. Wainwright
$4
Buy
146.91%
Upside
Reiterated
07/31/25
Actinium Pharmaceuticals' ATNM-400 Shows Promise in Prostate Cancer Treatment, Earning Buy RatingValuation and risks to price target achievement. We reiterate our Buy rating and $4 price target. Our current valuation includes only Actimab-A for AML (82% contribution) and Iomab-ACT, which recently had its IND approved (18% contribution). Our valuation is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug's potential commercial profile.
JonesTrading
$9
Buy
455.56%
Upside
Reiterated
06/25/25
Maxim Group
$5
Buy
208.64%
Upside
Reiterated
05/13/25
Stephens
$5
Buy
208.64%
Upside
Reiterated
11/19/24
B.Riley Financial
$16→$2
Hold
23.46%
Upside
Downgraded
08/07/24
Best Analysts Covering Actinium Pharmaceuticals
1 Month
xxx
Success Rate
7/14 ratings generated profit
Average Return
-1.51%
reiterated a xxx
rating 7 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of -1.51% per trade.
3 Months
xxx
Success Rate
7/14 ratings generated profit
Average Return
+1.21%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +1.21% per trade.
1 Year
Success Rate
6/14 ratings generated profit
Average Return
-28.00%
reiterated a buy rating 7 days ago
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 42.86% of your transactions generating a profit, with an average return of -28.00% per trade.
2 Years
xxx
Success Rate
6/14 ratings generated profit
Average Return
-26.66%
reiterated a xxx
rating 7 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 42.86% of your transactions generating a profit, with an average return of -26.66% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
ATNM Analyst Recommendation Trends
Rating
Mar 25
Apr 25
May 25
Jun 25
Jul 25
Strong Buy
11
14
17
9
7
Buy
0
0
0
0
0
Hold
1
2
1
1
0
Sell
1
3
3
3
0
Strong Sell
0
0
0
0
0
total
13
19
21
13
7
Each month's total comprises the sum of three months' worth of ratings.
ATNM Financial Forecast
ATNM Stock Forecast FAQ
What is ATNM’s average 12-month price target, according to analysts?
Based on analyst ratings, Actinium Pharmaceuticals’s 12-month average price target is 6.00.
What is ATNM’s upside potential, based on the analysts’ average price target?
Actinium Pharmaceuticals has 270.37% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is ATNM a Buy, Sell or Hold?
Actinium Pharmaceuticals has a consensus rating of Strong Buy which is based on 3 buy ratings, 0 hold ratings and 0 sell ratings.
What is Actinium Pharmaceuticals’s price target?
The average price target for Actinium Pharmaceuticals is 6.00. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $9.00 ,the lowest forecast is $4.00. The average price target represents 270.37% Increase from the current price of $1.62.
The highest analyst price target is $9.00 ,the lowest forecast is $4.00. The average price target represents 270.37% Increase from the current price of $1.62.
What do analysts say about Actinium Pharmaceuticals?
Actinium Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 3 Wall Streets Analysts.
How can I buy shares of ATNM?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.